Angiotensin signaling underlies myeloid and sensory disruption in diabetes

Active Grant Awarded Last action

Award ID
R01DK132019
Recipient
Awarding agency
Obligated
$1,636,191

Award facts

Completion date 64% complete
Place of performance
Houston, TX 77030, USA

Award details come from USAspending.gov.

Description

Abstract
Neuropathy associated with type 2 diabetes (T2D) is frequently associated with pain and sensory loss. Our incomplete mechanistic understanding of the pathophysiology of nerve injury in T2D hinders our ability to develop more effective drugs and therapeutic strategies. Given the emerging role of myeloid cells, particularly macrophages, across various types of neuropathy, their apparent involvement in diverse forms of nerve injury pain and the known increase in production of the peptide hormone angiotensin II (ANG II) in diabetes, we posit that elevated ANG II in T2D precipitates neuropathy, pain and sensory loss by disrupting myeloid cell development and phenotype. However, many knowledge gaps persist. Our preliminary studies indicate that circulating immature myeloid cell numbers are increased in diet-induced and genetic models of T2D, a change also associated with elevated levels of ANG II in lymphoid tissues. Furthermore, the sensory gain observed in diet-induced T2D is reversible by inhibitors of ANG II production. The overall goal of this project is to identify how ANG II disrupts myeloid cells in T2D, culminating in neuropathy, sensory loss and pain. The first specific aim will assess the extent of alterations to myelopoiesis across the progression from metabolic syndrome to early stage T2D to late-stage T2D, and whether increases in ANG II are causally related. The second specific aim will determine the degree to which T2D modifies tissue-resident myeloid cell function in ways that promote sensory dysfunction. Finally, the third specific aim will determine if opposing T2D-related changes in angiotensin signaling can normalize pathological changes to myeloid cells, thereby reducing sensory dysfunction. Our multidisciplinary approach involves preclinical T2D models, reflexive and voluntary pain-behavioral studies, immunohistochemistry, in vitro live cell functional imaging, single cell RNA and atac-sequencing and transcriptomic analysis of human skin biopsies. Our project will unambiguously dissect the nature of ANG II-based myeloid cell disruption to determine the role of the renin-angiotensin system and macrophage-driven inflammation in the development of peripheral neuropathy and chronic pain in T2D. Elucidating the mechanistic underpinnings of sensory loss and pain in T2D neuropathy is critical to advancing our understanding of the underlying mechanism(S), as well as rapid translation into development of new- generation, efficacious, non-opioid analgesics that target such neuro-immune crosstalk.

Transactions

Action Obligated Date
Amendment $187,920
Amendment $398,433
Amendment $109,933
Amendment $459,060
Original award $480,845

Subawards

Subrecipient Amount Awarded
Aarhus Universitet Pending $109,933

Quick answers

Who received award R01DK132019?

R01DK132019 was awarded to The Univeristy Of Texas M.d. Anderson Cancer Center by National Institute of Diabetes and Digestive and Kidney Diseases (National Institutes of Health) on May 2, 2024.

How much is award R01DK132019 worth?

$1,636,191 has been obligated on R01DK132019.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award